Northwestern University Feinberg School of Medicine

Center for Diabetes and Metabolism

Clinical Trials

The Center for Diabetes and Metabolism has numerous active clinical trials. Learn more about the current active protocols and participation opportunities via the list of below.

Northwestern University

PICoordinatorStudy Description
Grazia Aleppo, MDElaine Massaro
e-massaro( at )northwestern.edu
312-926-9628

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (DEPICT 2)

This study is a multicenter, randomized, double-blind, placebo-controlled, parallel group, phase 3 study to evaluate the efficacy and safety of Dapagliflozin, a SGLT2 inhibitor medication as an add-on to insulin therapy in subjects with Type 1 diabetes mellitus.

Grazia Aleppo, MDElaine Massaro
e-massaro( at )northwestern.edu
312-926-9628

A Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Type 1 Diabetes (REPLACE-BG)

The primary objective of the study is to determine whether the routine use of Continuous Glucose Monitoring (CGM) without Blood Glucose Monitoring (BGM) confirmation is as safe and effective as CGM used as an adjunct to BGM.

Mark E Molitch, MDDaphne Adelman
d-adelman( at )northwestern.edu
312-908-9002

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase III study to investigate the safety and efficacy of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with Type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease

Sponsor: Bayer Pharmaceuticals

Mark E Molitch, MDMariana Johns
mk-johnson( at )northwestern.edu
312-908-5565

Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3-Research Project

This study will examine the long-term effects of the early use – starting before diabetes develops – of metformin and lifestyle changes on development of significant morbidities such as cancer and cardiovascular disease, and help understand the clinical course of abnormal glucose levels from the pre-diabetic state through early and more advanced T2D.

Mark E Molitch, MDElaine Massaro
e-massaro( at )northwestern.edu
312-926-9628

Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Mellitus Patients Not Achieving Glycemic Targets on Basal Insulin With/Without Anti-Hyperglycemic Agents

Primary goal of this study is to compare the change in HbA1c with bolus insulin dosing with Finesse patch device system versus pen, from baseline to completion of basal and bolus therapy.

Sponsor: Calibra Pharmaceuticals

Mark E Molitch, MDDaphne Adelman
d-adelman( at )northwestern.edu
312-908-9002

Somatuline Depot (lanreotide) injection for Acromegaly (SODA): A Post-marketing Observational Study

The objectives of this post-marketing observational study are to assess the safety and effectiveness, as measured by insulin-like growth factor-1 (IGF-1) and growth hormone (GH) levels, of Somatuline® Depot (lanreotide) Injection when administered by a healthcare professional (HCP), the patient, the patient’s partner or parent/guardian as part of their routine acromegaly care. Treatment convenience and acromegaly symptom relief will also be assessed through questionnaires.

Mark E Molitch, MDDaphne Adelman
d-adelman( at )northwestern.edu
312-908-9002

Urinary Renin Angiotensin System in Diabetes

Angiotensinogen and renin will be measured in urine samples from participants of the Diabetes Control and Complications Trial (DCCT) study under the hypothesis that these two urine analytes will provide an early signature of kidney RAS system activation that antedates albuminuria in subjects with type 1 diabetes. Moreover, it is hypothesized that improved metabolic control, as provided by intensive insulin therapy, exerts a more effective suppressive effect on urinary angiotensinogen and/or renin RAS as compared to conventional insulin therapy.

Mark E Molitch, MDDaphne Adelman
d-adelman( at )northwestern.edu
312-908-9002

Vitamin D and type 2 Diabetes (D2D)

The goal of the Vitamin D and type 2 diabetes (D2D) study is to determine if vitamin D supplementation works to delay the onset of type 2 Diabetes in people at risk for the disease and to gain a better understanding of how Vitamin D affects glucose (sugar) metabolism.

Mark E Molitch, MDDaphne Adelman
d-adelman( at )northwestern.edu
312-908-9002

PERL: Implementing multicenter clinical trial of allopurinol to prevent renal function (GFR) loss in Type 1 Diabetes

Multicenter clinical trial to determine whether lowering serum uric acid by means of allopurinol early in the course of kidney disease may be effective in preventing or slowing the decline of renal function in T1D patients.

Mark E Molitch, MDDaphne Adelman
d-adelman( at )northwestern.edu
312-908-9002

Epidemiology of Diabetes Interventions and Complications (EDIC) Supplement: Residual Beta Cell Function in Patients with Long-Term Type 1 Diabetes

Supplemental study to DK094157 to assess measurements of C-peptide in plasma and urine to determine the incidence and strength of beta-cell function in EDIC participants.

Mark E Molitch, MDDaphne Adelman
d-adelman( at )northwestern.edu
312-908-9002

Epidemiology of Diabetes Interventions and Complications (EDIC) Supplement: Hearing Impairment in Long Term Type 1 Diabetes

Supplemental study to DK094157, focusing on assessing the hearing status of subjects with Type 1 Diabetes currently enrolled in the EDIC study.  Effort for the PI is subsumed under the main project, U01 DK094157-03.

Mark E Molitch, MDDaphne Adelman
d-adelman( at )northwestern.edu
312-908-9002

Epidemiology of Diabetes Interventions and Complications (EDIC)

This multicenter study is essentially a long-term observational study of the subjects who participated in the Diabetes Control and Complications Trial (DCCT). Subjects will have assessments of eyes, kidneys, and vascular system performed after one to five years using techniques used in the DCCT.

Lurie Children's Hospital

PICoordinatorStudy Description
Wendy Brickman, MDPaula Petrie, RN, CDE
pipetrie( at )luriechildrens.org
312-227-6502

Long-Term Investigative Follow-Up in TrialNet (LIFT) Study

This study is monitoring people early in the disease process immediately following diagnosis, as well as provides follow-up to those previously enrolled in TrialNet new onset diabetes studies.

 

Wendy Brickman, MDPaula Petrie, RN, CDE
pipetrie( at )luriechildrens.org
312-227-6502

Pathway to Prevention

This study screens and observes relatives of people with type 1 diabetes to learn more about how the disease occurs.